Dr Batchelor will lead the company’s pursuit of discovering and developing small molecules and biologics to guide cell fate for therapeutic purposes.
Dr Batchelor brings more than 28 years of experience in drug discovery and development, serving most recently as senior vice president at GlaxoSmithKline. During his career, he has advanced 11 drug candidates from target identification to positive completion of Phase II clinical studies.
Paul Grayson, president and CEO of Fate Therapeutics, said: “Ken Batchelor has a patient-centered approach that has led to a successful career translating discoveries into the clinic. Combining the company’s unmatched knowledge of stem cell biology with Ken’s experience in small molecule drug discovery and development across multiple therapeutic areas will accelerate our pursuit of revolutionary medicines.”